EVENTS · RYTM
PEERS
EARNINGS
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases. The company’s lead product, IMCIVREE (setmelanotide), is a precision medicine used to treat severe obesity and hyperphagia associated with specific melanocortin-4 receptor pathway disorders and acquired hypothalamic obesity. Rhythm Pharmaceuticals serves patients with serious rare conditions that are often underserved by conventional obesity treatments, and its work centers on targeted treatments designed for defined genetic and clinical populations. Based in Boston, Massachusetts, and founded in 2008, the company operates within specialty medicine, where it addresses unmet needs in rare metabolic and endocrine diseases through approved therapies and ongoing clinical development.
Rhythm Pharmaceuticals rose after NICE updated its guidance to cover IMCIVREE for adults with Bardet-Biedl syndrome, expanding the drug's reach in the UK
| Series | 1W | 1M |
|---|---|---|
| RYTM | +20.3% | +21.9% |
| Peers | +1.4% | +5.1% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 99 | 93 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | −0.68 | −0.61 | +10.29% | +18.45% |
| Q2 FY2026 | −0.84 | −0.73 | +12.85% | +7.72% |
| Q1 FY2026 | −0.87 | −0.83 | +4.56% | +12.89% |
| Q4 FY2025 | −0.84 | −0.73 | +12.89% | −6.48% |
| Q3 FY2025 | −0.74 | −0.82 | −11.05% | −12.55% |
| Series | 1W | 1M |
|---|---|---|
| RYTM | +20.3% | +21.9% |
| Peers | +1.4% | +5.1% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 99 | 93 |
